Exendin (9-39) is a well-characterized, competitive antagonist of glucagon-like peptide-1
(GLP-1) at its receptor.
These comprise of a long acting glucagon-like peptide-1
(GLP-1) receptor agonist, a per week insulin and a GLP-1 and insulin that act in together.
Dulaglutide, a glucagon-like peptide-1
receptor agonist administered subcutaneously once a week, has been approved for treatment of adults with type 2 diabetes, the Food and Drug Administration has announced.
GLP-1 or glucagon-like peptide-1
is a hormone that slows the tummy from emptying, thereby stimulating insulin production.
In addition, a blunted secretion and/or action of incretin hormones glucagon-like peptide-1
(GLP-1) and gastric inhibitory polypeptide (GIP) from the gastro-intestinal tract in response to a meal are also characteristic of T2DM.
They identified 42 randomized trials of DDP-4 inhibitors and 13 trials of glucagon-like peptide-1
(GLP-1) agonists that qualified.
, or GLP-1, drugs work by stimulating insulin release when glucose levels become too high.
Known as glucagon-like peptide-1
, or GLP-1, the hormone is naturally secreted from the intestine when we eat.
Medications update: Victoza for diabetes The Federal Aviation Administration has established certification procedures for a new diabetes medication, Victoza (liraglutide), a once-daily injectable medication called a glucagon-like peptide-1
receptor agonist (GLP-1).
Liraglutide is a human analogue of glucagon-like peptide-1
Cell and molecular biology of the incretin hormones glucagon-like peptide-1
and glucose-dependent insulin releasing polypeptide.
7-36: a physiological incretin in man.